 |
 |
 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
|
[Vol.33 No.4 contents] Japanese / English |
|
| ArticleTitle | Serotypes of Streptococcus pneumoniae in the Tokyo metropolitan area after pneumococcal vaccine introduction in Japan |
| Language | J |
| AuthorList | Takashi Ando1), Masaki Miyasaka2), Takahiro Masaki2), Midori Kono2), Yuko Nagano3), Kazumi Sakamoto4), Taku Tamura5), Masaki Abe1), Hiroshi Takeda6), Koji Nakada1,2), Yukiko Takarabe7), Yumiko Suzuki7), Hideaki Hanaki7), Sae Ochi2), Tomokazu Matsuura2) |
| Affiliation |
1) Department of Clinical Laboratory, The Jikei University Daisan Hospital 2) Department of Laboratory Medicine, The Jikei University School of Medicine 3) Department of Clinical Laboratory, The Jikei University Kashiwa Hospital 4) Department of Clinical Laboratory, The Jikei University Katsushika Medical Center 5) Department of Central Clinical Laboratory, The Jikei University Hospital 6) Department of Infectious Diseases and Infection Control, The Jikei University Daisan Hospital 7) Infection Control Research Center, Ōmura Satoshi Memorial Institute, Kitasato University |
| Publication | J.J.C.M.: 33 (4), 260-267, 2023 |
| Received | January 20, 2023 |
| Accepted | May 10, 2023 |
| Abstract | Introduction: This study aimed to survey the serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates in the Tokyo metropolitan area after pneumococcal vaccine introduction. Methods: From January 2018 to March 2019, target strains were isolated from patients at four university-affiliated hospitals in the Tokyo metropolitan area. Pneumococcal serotypes were identified using the slide agglutination test and capsular Quellung reaction using antiserum. Results: We analyzed 179 isolates, including 166 (92.7%) sputum isolates, 5 (2.8%) blood isolates, 4 (2.2%) otorrhea/middle ear fluid isolates, and 4 (2.2%) other isolates. The leading serotype isolated was 35B (n = 27; 15.1%), serotype 3 (n = 19; 10.6%), and 15A (n = 14; 7.8%). The distribution of serotype groups was 0.6% (n = 1) for the 7-valent pneumococcal conjugate vaccine (PCV7), 17.3% (n = 31) for 13-valent pneumococcal conjugate vaccine (PCV13)-nonPCV7, 24.6% (n = 44) for 23-valent pneumococcal polysaccharide vaccine-nonPCV13, and 57.5% (n = 103) for the non-vaccine type. Comparison of antimicrobial susceptibility between serotype groups showed that the intermediate and resistant percentages of penicillin G and meropenem were significantly higher in non-vaccine type (P < 0.05). High frequencies of type 35B and type 15A, which are non-sensitive to these antimicrobial agents, were isolated. Conclusions: Our results suggested that the vaccine introduction prevented the prevalence of serotypes included in PCV7 but not that of serotype 3 included in PCV13. Non-vaccine types were isolated more frequently and showed a tendency toward drug resistance. This study suggests that non-vaccine types of S. pneumoniae should be noted. |
| Keywords | Streptococcus pneumoniae, 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Japan |
| Copyright © 2002 The Japanese Society for Clinical Microbiology All rights reserved. |